Skip to content
Screener

Eli Lilly LLY Reportable Segment — Revenue

Similar metrics at other companies

Adobe logo
ADBEReportable Segment — Revenue
$6.62B+12.7%
BitGo Holdings logo
BTGOReportable Segment — Revenue
$3.77B+113%
Archer Aviation logo
ACHRReportable Segment — Revenue
$1.6M
Energy Vault Holdings logo
NRGVReportable Segment — Revenue
$21.88M+156%
Nextpower Inc. logo
NXTReportable Segment — Revenue
$880.52M-4.7%
Guardant Health logo
GHReportable Segment — Revenue
$301.67M+48.3%

Other financials

Income statement

See full
Revenue$23.0B+47.7%
Gross profit$19.7B+50.3%
Net income$7.1B+25.3%
EPS (diluted)$7.94+26.2%

Balance sheet

See full
Cash & equivalents$9.0B+165%
Total debt$54.9B+37.6%
Total equity$33.9B+85.4%
Total assets$142.28B+41.0%

Cash flow

See full
Operating cash flow$10.7B+246%
CapEx$2.9B+72.8%
Free cash flow$7.8B+458%

Valuation

See full
Market cap$1.06T+58.6%
Enterprise value$1.11T+56.9%
P/E39.8×-8.8×
P/S13.3×+0.8×

Profitability

See full
Gross margin83.4%+0.8pp
Net margin33.5%+7.6pp
FCF margin22.8%+13.7pp

Returns & leverage

See full
Return on equity102.4%+15.7pp
Debt / equity1.6×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:40 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000059478-26-000081
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$22,974$15,558$42,773$28,286
Less:
Cost of sales3,2682,4486,8454,672
Early-stage research and development(1)1,4501,1562,7152,146
Late-stage research and development(1)2,3682,1804,6133,924
Marketing, selling, and administrative3,4302,7536,3645,221
Acquired in-process research and development2,7761543,3601,726
Other segment items(2)2,5871,2074,3842,177

Item 1. Financial Statements

FAQ

What is Eli Lilly's reportable segment — revenue?
Eli Lilly (LLY) reported reportable segment — revenue of $22.97B in Q2 2026.
How has Eli Lilly's reportable segment — revenue changed year-over-year?
Eli Lilly's reportable segment — revenue increased by 47.7% year-over-year, from $15.56B to $22.97B.
What is the long-term trend for Eli Lilly's reportable segment — revenue?
Over 3 years (2022 to 2025), Eli Lilly's reportable segment — revenue has grown at a 31.7% compound annual growth rate (CAGR), from $28.54B to $65.18B.
What does reportable segment — revenue mean?
Represents the total gross inflow of economic benefits arising from the ordinary operating activities of the reportable business segment. This metric reflects the market demand for the segment's specific portfolio of pharmaceutical products and services. It serves as the primary indicator of the segment's top-line growth and market penetration.

Ask your AI about Eli Lilly's reportable segment — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude